Literature DB >> 26079459

Quality of Life of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving High-Dose Cisplatin Chemotherapy and Radiotherapy.

Marília Berlofa Visacri1, Graziele Baldan Ferrari1, Pâmela Dias1, Rafaela Pimentel1, Cinthia Madeira de Souza1, Anna Paula Lourenço Costa1, Eder de Carvalho Pincinato1, Carmen Silvia Passos Lima1, Priscila Gava Mazzola1, Patricia Moriel1.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the quality of life (QOL) of patients with squamous cell carcinoma of the head and neck before and during treatment with high-dose cisplatin and radiotherapy.
METHODS: This was an observational and longitudinal prospective study conducted from June 2011 to March 2013 at the clinical oncology ambulatory unit of a public teaching hospital in São Paulo, Brazil. The University of Washington Quality of Life Questionnaire was used to measure the QOL of patients before and after each chemotherapy cycle with high-dose cisplatin (80-100 mg/m(2), three cycles) and radiotherapy (2 Gy, 5 days/week for 7 weeks). Data were analyzed using Student t tests, and P < 0.05 was considered statistically significant.
RESULTS: Thirty-two patients completed the three cycles of treatment. The study population consisted primarily of white men with a mean age older than 50 years, who had a partner, a low education level, and who were heavy smokers and drinkers, Karnofsky Performance Status of 90% to 100%, pharynx tumors, and stage IV cancer, classified as T4 and N2 stages; the minority of them required interventions such as a feeding tube and tracheostomy. We observed a reduction in QOL after treatment initiation; this reduction was significant after the second chemotherapy cycle and the sixth week of radiotherapy. The abilities to taste, swallow, salivate, and participate in activities and recreation were affected significantly. We also observed a significant improvement in pain and anxiety resulting from the chemoradiation.
CONCLUSIONS: Healthcare providers need to be aware of the affected domains to provide improved QOL, well-being, and security to cancer patients who are receiving this type of treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26079459     DOI: 10.14423/SMJ.0000000000000298

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

1.  Can acetylcysteine ameliorate cisplatin-induced toxicities and oxidative stress without decreasing antitumor efficacy? A randomized, double-blind, placebo-controlled trial involving patients with head and neck cancer.

Authors:  Marília B Visacri; Júlia C F Quintanilha; Vanessa M de Sousa; Laís S Amaral; Rosiane de F L Ambrósio; Luciane Calonga; Silvia F B B Curi; Mayra F de T Leme; Carlos T Chone; João M C Altemani; Priscila G Mazzola; Carina Malaguti; Aníbal E Vercesi; Carmen S P Lima; Patricia Moriel
Journal:  Cancer Med       Date:  2019-04-11       Impact factor: 4.452

2.  Head and Neck Cancer Patients' Quality of Life: Analysis of Three Instruments.

Authors:  Elâine Patrícia Alves de Araújo Gomes; Andreza Maria Fabio Aranha; Alvaro Henrique Borges; Luiz Evaristo Ricci Volpato
Journal:  J Dent (Shiraz)       Date:  2020-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.